// Biotech and Pharma Therapeutics
Germany And France Join Forces To Counter MFN And Other Threats To European Pharma
May 20, 2026 / European pharma / Drug pricing / Pharmaceutical innovation / Supply chain resilience / Healthcare policy
Germany and France pledged coordinated action to strengthen Europe’s pharmaceutical industry, addressing pressures from U.S. pricing policies, supply chain vulnerabilities, and rising Chinese competition while supporting innovation, manufacturing resilience, and long-term healthcare sovereignty.
Healthcare IT History Doesn’t Repeat, but It Does Rhyme
May 21, 2026 / Healthcare AI / EHR platforms / Digital health / AI governance / Health IT innovation
Healthcare AI adoption is following a familiar health IT pattern, with organizations initially deploying best-of-breed solutions before eventual consolidation into broader AI platforms, likely spanning EHRs, revenue cycle management, radiology, and operational workflows.
5 of the Most Expensive Medical Devices of 2026
May 20, 2026 / Medical devices / Robotic surgery / Healthcare costs / Imaging technology / Hospital spending
Rising adoption of advanced imaging systems, robotic surgery platforms, and cardiopulmonary technologies is driving substantial hospital spending, highlighting ongoing tension between innovation, operational costs, depreciation, and healthcare system affordability in the medical device market.
As Griffith retires, Dittrich returns to Amgen, takes CFO role
May 20, 2026 / Amgen / Biopharma leadership / CFO transition / Pharmaceutical industry / Corporate strategy
Amgen appointed former executive Thomas Dittrich as incoming CFO following Peter Griffith’s retirement, signaling leadership continuity as the company navigates growth initiatives, pipeline expansion, and financial strategy in a competitive biopharma environment.
3 big shifts for the GLP-1 market
May 21, 2026 / GLP-1 drugs / Obesity treatment / Medicare coverage / Weight-loss medications / Compounded semaglutide
The GLP-1 market is rapidly evolving through oral weight-loss drug launches, expanded Medicare coverage, and tighter FDA restrictions on compounded products, reshaping obesity treatment access, prescribing patterns, and long-term chronic disease management across U.S. healthcare.
// 4th Industrial Revolution
Machine learning lifestyle coaching helps reduce major depressive symptoms
May 21, 2026 / Depression treatment / Machine learning / Digital health / Lifestyle coaching / Mental health innovation
Researchers developed a machine learning-guided lifestyle coaching program that personalized sleep, exercise, diet, and social interventions, significantly reducing mild-to-moderate depressive symptoms and highlighting the growing role of digital mental health and precision behavioral care.
Mayo Clinic & Bayesian Health Co-Develop AI-Powered Solution to Expand Palliative Care Access
May 21, 2026 / Artificial intelligence / Palliative care / Clinical decision support / Hospital readmissions / Digital health
Mayo Clinic and Bayesian Health developed an AI-powered EHR-integrated platform that improves early identification of hospitalized patients needing palliative care, increasing timely referrals while reducing hospital readmissions and strengthening serious illness management through real-time clinical intelligence.
AI passed a classic Turing test by mastering the art of human small talk
May 20, 2026 / Artificial intelligence / Large language models / Turing test / Human-AI interaction / Machine learning
Researchers found advanced large language models could pass a classical three-party Turing test by mimicking human conversational behavior, highlighting how socio-emotional communication and conversational style increasingly enable AI systems to appear convincingly human in short interactions.
How an AI system learned to write expert-level scientific code
May 20, 2026 / Artificial intelligence / Scientific software / Machine learning / COVID-19 forecasting / Computational biology
Researchers developed ERA, an AI system combining large language models and tree search algorithms to autonomously generate expert-level scientific software, outperforming benchmark models in areas including COVID-19 forecasting, bioinformatics, and geospatial analysis while accelerating computational research workflows.
ChatCPR instructor delivers near-perfect CPR guidance in proof-of-concept study
May 20, 2026 / Artificial intelligence / CPR guidance / Cardiac arrest / Emergency medicine / Bystander CPR
A proof-of-concept study found the AI-based ChatCPR system delivered near-perfect, guideline-concordant CPR instructions, outperforming human dispatchers in simulated and archived 911 cardiac arrest scenarios, highlighting AI’s potential to improve bystander CPR quality and emergency response outcomes.
// Business & Markets
Engage Bio acquired by Lilly
May 21, 2026 / Eli Lilly / Biotech acquisition / DNA delivery / Biologics innovation / Therapeutic development
Eli Lilly acquired Engage Biologics, strengthening its capabilities in non-viral DNA delivery technologies and expanding its preclinical innovation pipeline in advanced biologics and next-generation therapeutic development.
GHO Capital, CBC Group Combine to Form $21B Healthcare Investment Giant
May 20, 2026 / Healthcare investment / Private equity / Biotech funding / Pharmaceutical innovation / Medical technology
GHO Capital and CBC Group plan to merge into a $21 billion healthcare investment platform, expanding global reach across biotech, pharma, medical technology, and healthcare services to support innovation, cross-border growth, and international healthcare commercialization.
Kin Health Raises $9M to Launch Free Conversational App for Patients
May 21, 2026 / Artificial intelligence / Digital health / Patient engagement / Clinical documentation / Healthcare technology
Kin Health raised $9 million to expand its free AI-powered app that records physician visits, converts conversations into plain-language summaries, and improves patient understanding, care adherence, and longitudinal health record management through consumer-focused ambient clinical intelligence.
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid
May 21, 2026 / Alzheimer’s disease / Neuroinflammation / Amyloid therapy / Tau protein / Neuroscience research
Bristol Myers Squibb is expanding its Alzheimer’s strategy beyond amyloid, advancing tau and neuroinflammation-focused therapies while exploring stress-response pathways like EIF2b to develop diversified disease-modifying and symptomatic neuroscience treatments.
Gilead pledges 400K AmBiosome doses to fight visceral leishmaniasis in expanded WHO collab
May 21, 2026 / Visceral leishmaniasis / Global health / AmBisome / World Health Organization / Infectious disease
Gilead and the WHO expanded their collaboration to combat visceral leishmaniasis, pledging 400,000 AmBisome doses and $9.2 million to improve treatment access, strengthen health systems, and accelerate disease elimination efforts in high-burden regions across East Africa and Asia.
// Legal & Regulatory
Guardant wins FDA approval for updated liquid biopsy
May 21, 2026 / Liquid biopsy / Precision oncology / Genomic profiling / Cancer diagnostics / FDA approval
The FDA approved Guardant Health’s expanded liquid biopsy test, enabling genomic profiling of more than 740 genes to improve precision oncology, biomarker detection, and personalized cancer treatment selection through minimally invasive blood-based diagnostics.
Chugai gains new Japanese approval for Alecensa
May 21, 2026 / Alecensa / Precision oncology / ALK inhibitor / Pediatric cancer / Targeted therapy
Chugai received Japanese regulatory approval to expand Alecensa’s use for advanced or recurrent ALK fusion-positive solid tumors, including pediatric patients, broadening targeted treatment options in precision oncology and rare cancer care.
Auchincloss developing clinical trials package to enhance U.S. competitiveness
May 20, 2026 / Clinical trials / Life sciences / FDA modernization / Healthcare innovation / Biopharmaceutical research
Rep. Jake Auchincloss is developing legislation to modernize U.S. clinical trials by embedding research into routine healthcare, streamlining early-stage studies, and strengthening American competitiveness in life sciences innovation ahead of PDUFA reauthorization.
Medtronic’s Acquisition Spree Continues: SPR Therapeutics Joins $650M Neuromodulation Expansion
May 20, 2025 / Neuromodulation / Chronic pain / Peripheral nerve stimulation / Medtronic / Medical devices
Medtronic will acquire SPR Therapeutics for $650 million, expanding its neuromodulation portfolio with minimally invasive peripheral nerve stimulation technology designed to improve chronic pain management and broaden earlier-stage patient access to non-opioid therapies.
Infex chases after Insmed with bronchiectasis trial win
May 21, 2026 / Bronchiectasis / Pseudomonas aeruginosa / Respiratory disease / Monoclonal antibody / Clinical trial
Infex Therapeutics reported positive phase 2a results for RESP-X in non-cystic fibrosis bronchiectasis, showing reduced exacerbations and favorable safety in patients with Pseudomonas aeruginosa, advancing competition in a growing market for chronic inflammatory lung disease therapies.
// Research & Development
Lilly’s triple agonist shows bariatric surgery–like weight loss results
May 21, 2026 / Retatrutide / Obesity treatment / GLP-1 therapy / Weight loss drugs / Bariatric surgery
Eli Lilly’s triple agonist retatrutide achieved up to 28.3% weight loss over 80 weeks in Phase 3 obesity trials, approaching bariatric surgery outcomes while improving cardiovascular risk markers, reinforcing the next-generation potential of multi-hormone obesity therapeutics.
Remepy’s app-drug combo heads for Phase III on mid-stage Parkinson’s win
May 21, 2026 / Parkinson’s disease / Digital therapeutics / Levodopa therapy / Neuroplasticity / Hybridopa
Remepy’s Hybridopa, combining levodopa with a digital therapeutic app, improved motor, daily living, and depressive symptoms in Parkinson’s patients during a Phase IIa trial, while MRI findings suggested enhanced neuroplasticity and brain connectivity ahead of planned Phase III development.
Qualtrics eyes a data engine to predict the experiences patients want
May 20, 2025 / Healthcare AI / Patient experience / Predictive analytics / Digital health / Workforce resilience
Qualtrics’ acquisition of Press Ganey Forsta expands its AI-driven healthcare experience platform, enabling predictive patient engagement, operational insights, and workforce resilience through real-time analysis of data from over 41,000 healthcare facilities.
First-of-its-kind pregnancy hormone test reveals why female IBD patients face severe symptom flares
May 21, 2025 / Inflammatory bowel disease / Women’s health / Organ-on-chip / Pregnancy hormones / Colorectal cancer
Researchers developed patient-specific colon organ-on-chip models showing pregnancy hormones exacerbate inflammatory bowel disease in women by increasing inflammation and fibrosis, while identifying stromal fibroblasts as key drivers of IBD progression and cancer risk.
Scientists discover the nutrient that can supercharge cellular energy
May 21, 2025 / Leucine / Mitochondrial function / Cellular energy / Metabolic disease / Cancer research
Researchers identified leucine as a key nutrient that enhances mitochondrial function by stabilizing energy-producing proteins, revealing a novel connection between dietary amino acids, cellular metabolism, and potential therapeutic strategies for metabolic diseases and cancer.
// Politics
Supreme Court rejects bid to halt IRA price negotiations
May 20, 2026 / Inflation Reduction Act / Medicare drug pricing / Pharmaceutical industry / Healthcare policy / Drug cost reform
The U.S. Supreme Court declined to hear pharmaceutical industry challenges to Medicare drug price negotiations under the Inflation Reduction Act, reinforcing federal authority to pursue cost-containment measures aimed at reducing prescription drug spending for patients and healthcare systems.
FDA chief Makary resigns amid political pressure, drug disputes
May 15, 2026 / FDA leadership / Drug regulation / Healthcare policy / Pharmaceutical oversight / Marty Makary
FDA Commissioner Marty Makary resigned following political and regulatory conflicts involving drug approvals, abortion policy, and vaping oversight, creating uncertainty around future FDA leadership, regulatory stability, and U.S. pharmaceutical policy direction.
Sen. David McCormick tours AI-powered biotech labs at Penn to promote AI and federal funding admit NSF turmoil
May 18, 2026 / Artificial intelligence / Drug discovery / RNA therapeutics / Biotechnology innovation / Precision medicine
Sen. Dave McCormick highlighted AI-driven biomedical innovation at Penn’s AIRFoundry, where researchers are using artificial intelligence, robotics, and automation to dramatically accelerate RNA drug discovery, lower development costs, and expand U.S. biotech competitiveness.
MHRA proposes new framework to accelerate rare disease therapies in UK
May 21, 2026 / Rare diseases / MHRA / Drug approval / Regulatory innovation / Orphan therapies
The UK MHRA launched a proposed Rare Disease Therapies Framework aimed at accelerating regulatory review and patient access for rare and ultra-rare disease treatments through more flexible, innovation-focused approval pathways.
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
May 20, 2026 / Ebola outbreak / Antibody therapy / Infectious diseases / Biopharmaceuticals / Global health
The U.S. government partnered with Mapp Biopharmaceutical to deploy an experimental antibody therapy during the worsening Ebola outbreak in central Africa, highlighting ongoing efforts to expand rapid-response treatments for emerging infectious disease threats.